{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:01:08Z","timestamp":1792195268802,"version":"4.4.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T00:00:00Z","timestamp":1707868800000},"content-version":"am","delay-in-days":378,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","award":["HHSN272201300018I\/HHSN27200021"],"award-info":[{"award-number":["HHSN272201300018I\/HHSN27200021"]}],"id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI148574"],"award-info":[{"award-number":["AI148574"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["T32AI074492"],"award-info":[{"award-number":["T32AI074492"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.vaccine.2023.01.059","type":"journal-article","created":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T22:26:35Z","timestamp":1675117595000},"page":"1513-1523","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Cellular and humoral immunity to Ebola Zaire glycoprotein and viral vector proteins following immunization with recombinant vesicular stomatitis virus-based Ebola vaccine (rVSV\u0394G-ZEBOV-GP)"],"prefix":"10.1016","volume":"41","author":[{"given":"Vanessa","family":"Raabe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilin","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliet","family":"Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Rouphael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard T.","family":"Davey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Mulligan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2023.01.059_b0005","unstructured":"Centers for Disease Control and Prevention. 2014-2016 Ebola Outbreak in West Africa. 8 March 2019 [cited 2021 1 July]; Available from: https:\/\/www.cdc.gov\/vhf\/ebola\/history\/2014-2016-outbreak\/index.html."},{"key":"10.1016\/j.vaccine.2023.01.059_b0010","unstructured":"World Health Organization. 10th Ebola outbreak in the Democratic Republic of the Congo declared over; vigilance against flare-ups and support for survivors must continue. 2020 25 June [cited 2021 1 July]; Available from: https:\/\/www.who.int\/news\/item\/25-06-2020-10th-ebola-outbreak-in-the-democratic-republic-of-the-congo-declared-over-vigilance-against-flare-ups-and-support-for-survivors-must-continue."},{"key":"10.1016\/j.vaccine.2023.01.059_b0015","unstructured":"European Medicines Agency. Ebola. 2019 [cited 2021 June 25]; Available from: https:\/\/www.ema.europa.eu\/en\/human-regulatory\/overview\/public-health-threats\/ebola."},{"key":"10.1016\/j.vaccine.2023.01.059_b0020","unstructured":"Merck Sharp & Dohme Corp. ERVEBO\u00ae(Ebola Zaire Vaccine, Live) Suspension for intramuscular injection [package insert]. US Food and Drug Administration Website. https:\/\/wwwfdagov\/media\/133748\/download. Accessed 1 July 2021."},{"key":"10.1016\/j.vaccine.2023.01.059_b0025","unstructured":"World Health Organization. Preliminary results on the efficacy of rVSV-ZEBOV-GP Ebola vaccine using the ring vaccination strategy in the control of an Ebola outbreak in the Democratic Republic of the Congo: an example of integration of research into epidemic response. 2019.[cited 2021 1 July]; Available from: https:\/\/www.who.int\/csr\/resources\/publications\/ebola\/ebola-ring-vaccination-results-12-april-2019.pdf?ua=1."},{"key":"10.1016\/j.vaccine.2023.01.059_b0030","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ebiom.2017.03.045","article-title":"Dose-dependent T-cell dynamics and cytokine cascade following rVSV-ZEBOV immunization","volume":"19","author":"Dahlke","year":"2017","journal-title":"EBioMedicine"},{"key":"10.1016\/j.vaccine.2023.01.059_b0035","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1073\/pnas.1209591110","article-title":"Antibodies are necessary for rVSV\/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates","volume":"110","author":"Marzi","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2023.01.059_b0040","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/s41598-017-01032-8","article-title":"Transcriptomic analysis reveals a previously unknown role for CD8(+) T-cells in rVSV-EBOV mediated protection","volume":"7","author":"Menicucci","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2023.01.059_b0045","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1016\/j.vaccine.2020.04.061","article-title":"Serostatus cutoff levels and fold increase to define seroresponse to recombinant vesicular stomatitis virus - Zaire Ebola virus envelope glycoprotein vaccine: an evidence-based analysis","volume":"38","author":"Antonello","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.01.059_b0050","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/S0140-6736(08)61591-3","article-title":"Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial","volume":"372","author":"Buchbinder","year":"2008","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.vaccine.2023.01.059_b0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006888","article-title":"Distinct susceptibility of HIV vaccine vector-induced CD4 T cells to HIV infection","volume":"14","author":"Auclair","year":"2018","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2023.01.059_b0060","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1172\/JCI60202","article-title":"Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine","volume":"122","author":"Frahm","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2023.01.059_b0065","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1084\/jem.20081786","article-title":"Activation of a dendritic cell-T cell axis by Ad5 immune complexes creates an improved environment for replication of HIV in T cells","volume":"205","author":"Perreau","year":"2008","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2023.01.059_b0070","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.1128\/JVI.73.5.3723-3732.1999","article-title":"Attenuated vesicular stomatitis viruses as vaccine vectors","volume":"73","author":"Roberts","year":"1999","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2023.01.059_b0075","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3201\/eid2102.141649","article-title":"Vesicular stomatitis virus-based vaccines against Lassa and Ebola viruses","volume":"21","author":"Marzi","year":"2015","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2023.01.059_b0080","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1093\/infdis\/jiy565","article-title":"Detectable vesicular stomatitis virus (VSV)-specific humoral and cellular immune responses following VSV-Ebola virus vaccination in humans","volume":"219","author":"Poetsch","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2023.01.059_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2022.09.037","article-title":"Immunogenicity of rVSV\u0394G-ZEBOV-GP Ebola vaccine (ERVEBO\u00ae) in African clinical trial participants by age, sex, and baseline GP-ELISA titer: A post hoc analysis of three Phase 2\/3 trials","author":"Simon","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.01.059_b0095","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1038\/nm.4201","article-title":"Human antibody repertoire after VSV-Ebola vaccination identifies novel targets and virus-neutralizing IgM antibodies","volume":"22","author":"Khurana","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2023.01.059_b0100","first-page":"12","article-title":"Ebola virus disease survivors show more efficient antibody immunity than vaccinees despite similar levels of circulating immunoglobulins","author":"Koch","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2023.01.059_b0105","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/nm.2447","article-title":"CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates","volume":"17","author":"Sullivan","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2023.01.059_b0110","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines10040533","article-title":"Protective CD8+ T cell response induced by modified Vaccinia virus Ankara delivering Ebola virus nucleoprotein","author":"Kupke","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2023.01.059_b0115","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/BF00196682","article-title":"Immunization with recombinant protein: conditions for cytotoxic T cell and\/or antibody induction","volume":"183","author":"Bachmann","year":"1994","journal-title":"Med Microbiol Immunol"},{"key":"10.1016\/j.vaccine.2023.01.059_b0120","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1128\/jvi.10.6.1231-1235.1972","article-title":"The glycoprotein of vesicular stomatitis virus is the antigen that gives rise to and reacts with neutralizing antibody","volume":"10","author":"Kelley","year":"1972","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2023.01.059_b0125","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/0042-6822(82)90125-8","article-title":"The interaction of antibody with the major surface glycoprotein of vesicular stomatitis virus. I. analysis of neutralizing epitopes with monoclonal antibodies","volume":"121","author":"Lefrancios","year":"1982","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2023.01.059_b0130","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/0042-6822(86)90328-4","article-title":"Sequences of the major antibody binding epitopes of the Indiana serotype of vesicular stomatitis virus","volume":"148","author":"Vandepol","year":"1986","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2023.01.059_b0135","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1128\/jvi.69.4.2153-2158.1995","article-title":"Antiviral protection by vesicular stomatitis virus-specific antibodies in alpha\/beta interferon receptor-deficient mice","volume":"69","author":"Steinhoff","year":"1995","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2023.01.059_b0140","first-page":"175","article-title":"The role of antibodies in natural and acquired resistance of mice to vesicular stomatitis virus","volume":"56","author":"Gobet","year":"1988","journal-title":"Exp Cell Biol"},{"key":"10.1016\/j.vaccine.2023.01.059_b0145","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1128\/jvi.51.1.208-214.1984","article-title":"Protection against lethal viral infection by neutralizing and nonneutralizing monoclonal antibodies: Distinct mechanisms of action in vivo","volume":"51","author":"Lefrancois","year":"1984","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2023.01.059_b0150","doi-asserted-by":"crossref","first-page":"4897","DOI":"10.1128\/JVI.03276-13","article-title":"VSV-GP: a potent viral vaccine vector that boosts the immune response upon repeated applications","volume":"88","author":"Tober","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2023.01.059_b0160","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1128\/jvi.60.2.708-717.1986","article-title":"N protein is the predominant antigen recognized by vesicular stomatitis virus-specific cytotoxic T cells","volume":"60","author":"Puddington","year":"1986","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2023.01.059_b0165","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.1128\/JVI.05991-11","article-title":"The immune response to a vesicular stomatitis virus vaccine vector is independent of particulate antigen secretion and protein turnover rate","volume":"86","author":"Cobleigh","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2023.01.059_b0170","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/348213a0","article-title":"Isolation of an endogenously processed immunodominant viral peptide from the class I H-2Kb molecule","volume":"348","author":"Van Bleek","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2023.01.059_b0175","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1084\/jem.163.6.1529","article-title":"Recognition of cloned vesicular stomatitis virus internal and external gene products by cytotoxic T lymphocytes","volume":"163","author":"Yewdell","year":"1986","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2023.01.059_b0180","doi-asserted-by":"crossref","first-page":"27944","DOI":"10.1038\/srep27944","article-title":"Circulating follicular T helper cells and cytokine profile in humans following vaccination with the rVSV-ZEBOV Ebola vaccine","volume":"6","author":"Farooq","year":"2016","journal-title":"Scientific reports"},{"key":"10.1016\/j.vaccine.2023.01.059_b0185","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1002\/art.1780360713","article-title":"Antibodies to vesicular stomatitis virus proteins in patients with systemic lupus erythematosus and in normal subjects","volume":"36","author":"Hardgrave","year":"1993","journal-title":"Arthritis Rheum"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23000907?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23000907?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:22:40Z","timestamp":1759404160000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23000907"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S0264410X23000907"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.01.059","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.11.09.21266118","asserted-by":"object"}]},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cellular and humoral immunity to Ebola Zaire glycoprotein and viral vector proteins following immunization with recombinant vesicular stomatitis virus-based Ebola vaccine (rVSV\u0394G-ZEBOV-GP)","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.01.059","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}